Treatment adherence in tyrosinemia type 1 patients

BACKGROUND: While therapeutic advances have significantly improved the prognosis of patients with hereditary tyrosinemia type 1 (HT1), adherence to dietary and pharmacological treatments is essential for an optimal clinical outcome. Poor treatment adherence is well documented among patients with chr...

Descripción completa

Detalles Bibliográficos
Autores principales: González-Lamuño, Domingo, Sánchez-Pintos, Paula, Andrade, Fernando, Couce, María L., Aldámiz-Echevarría, Luís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173906/
https://www.ncbi.nlm.nih.gov/pubmed/34082789
http://dx.doi.org/10.1186/s13023-021-01879-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173906/
https://www.ncbi.nlm.nih.gov/pubmed/34082789
http://dx.doi.org/10.1186/s13023-021-01879-1

Ejemplares similares